胰岛素在糖尿病（diabetes mellitus，DM）治疗管理中至关重要，但胰岛素治疗惰性普遍存在，严重影响患者血糖控制与疾病进展，其成因涉及医患双重因素。为优化血糖控制方案、消除治疗顾虑、提升患者依从性与治疗持续性，基础胰岛素周制剂应运而生。本文从胰岛素治疗惰性视角，聚焦基础胰岛素周制剂的创新价值与突破意义。
基础胰岛素；治疗惰性；周制剂；2 型糖尿病；血糖管理；患者依从性
[1]Khunti K,Gomes MB,Pocock S,et al．Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes:a systematic review[J]．Diabetes Obes Metab,2018,20(2):427-437．
[2]Correa MF,Li Y,Kum HC,et al．Assessing the effect of clinical inertia on diabetes outcomes:a modeling approach[J]．J Gen InternMed,2019,34(3):372-378．
[3]Phillips LS,Branch WT,Cook CB,et al．Clinical inertia[J]．AnnIntern Med,2001,135(9):825-834．
[4]Andrade SE,Gurwitz JH,Field TS,et al．Hypertension management:the care gap between clinical guidelines and clinical practice[J]．Am J Manag Care,2004,10(7Pt 2):481-486.
[5]王坤林,宰国田,徐海波,等.2型糖尿病患者治疗过程中的临床惰性及其影响因素[J].中国临床研究,2022,35(7):967-971.
[6]Reach G．Clinical inertia:a critique of medical reason[M]．Switzerland:Springer-Verlag,2015.
[7]Khunti,K,Millar-Jones,D.Clinical inertia to insulin initiation and intensification in the UK:A focused literature review[J].PRIM CARE DIABETES.2017,11(1):3-12.
[8]Fu,AZ,Sheehan,JJ.Treatment intensification for patients with type 2 diabetes and poor glycaemic control[J].DIABETES OBES METAB.2016;18(9):892-8.
[9]Mauricio,D,Meneghini,L,Seufert,J,et al.Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA[J].DIABETES OBES METAB.2017,19(8):1155-1164.
[10]Jabbar,A,Abdallah,K,Hassoun,A,et al.Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region[J].DIABETES RES CLIN PR.2019(149):18-26.
[11]Jabbar,A,Mohamed,WMIBW,Ozaki,R,et al.Patterns and trends in insulin initiation and intensification among patients with type 2 diabetes mellitus in the Western Pacific region[J].CURR MED RES OPIN.2018,34(9):1653-1662.
[12]Ji,L,Zhang,P,Zhu,D,et al.Observational Registry of Basal Insulin Treatment(ORBIT)in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs:Real-life use of basal insulin in China[J].DIABETES OBES METAB.2017,19(6):822-830.
[13]Ji,L,Zhang,P,Weng,J,et al.Observational Registry of Basal Insulin Treatment(ORBIT)in Patients
with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China--Study Design and
Baseline Characteristics.DIABETES TECHNOL THE[J].2015,17(10):735-44.
[14]Mocarski,M,Yeaw,J,Divino,V,et al.Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes[J].J MANAG CARE SPEC PH.2018,24(4):390-400.
[15]Khunti,K,Nikolajsen,A,Thorsted,BL,et al.Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin[J].DIABETES OBES METAB.2016,18(4):401-9.
[16]Gavin JR,Abaniel RM,Virdi NS.Therapeutic Inertia and Delays in Insulin Intensification in
Type 2 Diabetes:A Literature Review[J].Diabetes Spectr.2023,36(4):379-384.
[17]Rodriguez,P,San Martin,VT,Pantalone,KM.Therapeutic Inertia in the Management of Type
2 Diabetes:A Narrative Review[J].DIABETES THER.2023,15(3):567-583.
[18]Galdón Sanz-Pastor,A,Justel Enríquez,A,Sánchez Bao,A,et al.Current barriers to initiating insulin therapy in individuals with type 2 diabetes[J].Front Endocrinol(Lausanne).2023,15 1366368.
[19]Peyrot,M,Barnett,AH,Meneghini,LF,et al.Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin
Therapy study[J].DIABETIC MED.2012,29(5):682-9.
[20]杨文英.基础胰岛素治疗的临床惰性与治疗优化[J].中国糖尿病杂志,2022,30(02):151-153.
[21]Kerr,D,Rajpura,JR,Namvar,T.Evaluating Patient and Provider Preferences for a Once-Weekly Basal Insulin in Adults with Type 2 Diabetes[J].Patient Prefer Adherence.2023,18 411-424.
[22]Rosenstock,J,Del Prato,S.Basal weekly insulins:the way of the future!METABOLISM.2022;126 154924.
[23]Nishimura E,Pridal L,Glendorf T,et al.Molecular and pharmacological characterization of insulin icodec:a new basal insulin analog designed for once weekly dosing[J].BMJ Open Diabetes Res Care,2021,9(1):e002301.
[24]DiMarchi RD,Mayer JP.Icodec advances the prospect of once weekly insulin injection[J].J Med
Chem,2021,64(13):8939 8941.
[25]Kjeldsen TB,Hubálek F,Hjørringgaard CU,et al.Molecular engineering of insulin Icodec,the first
acylated insulin analog for once weekly administration in humans[J].J Med Chem,2021,64(13):8942 8950.
[26]Rosenstock J,Bajaj HS,JanežA,et al.Once weekly insulin for type 2 diabetes without previous insulin treatment[J].N Engl J Med,2020,383(22):2107 2116.
[27]PHILIS-TSMIKAS A,BAJAJ HS,BEGTRUP K,et al.Rationale and design of the phase 3 development programme(ONWARDS 1-6 trials)investigating once-weekly insulin icodec in diabetes[J].Diabetes Obes Metab,2023,25(2):331-341.
[28]Bergenstal,Richard M,Philis‐Tsimikas,et al.Pharmacokinetic and pharmacodynamic properties
of the novel basal insulin Fc(insulin efsitora alfa),an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.DIABETES OBES METAB.2023V25N4:1080-1090.
[29]Frias,J,Chien,J,Zhang,Q,et al.Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin:a multicentre,open-label,randomised,phase 2 study[J].LANCET DIABETES ENDO.2023,11(3):158-168.
[30]ADA 2022 POSTER.Once Weekly(QW)Basal Insulin Fc(BIF)Demonstrated Similar Glycemic Control to Once Daily Insulin Degludec in Insulin-naive Patients with Type 2 Diabetes(T2D).
[31]Kazda CM,Bue-Valleskey JM,Chien,J,et al.Novel Once-Weekly Basal Insulin Fc Achieved Similar
Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes[J].DIABETES CARE.2023,46(5):1052-1059.
[32]Bergenstal,Richard M,Philis‐Tsimikas,et al.Once‐weekly insulin efsitora alfa:Design and rationale for the QWINT phase 3 clinical development programme[J].Diabetes,obesity&metabolism,2024,26(8):3020-3030.
[33]Tang,C,Su,R,Wan,L,et al.Safety,tolerability,phar macokinetics and pharmacodynamics of GZR4,a novel once-weekly basal insulin,in healthy participants:A randomized trial.DIABETES OBES
METAB.2023,27(5):2515-2522.
[34]Tang,C,Su,R,Wan,L,et al.Safety,tolerability,phar macokinetics and pharmacodynamics of GZR4,a novel once-weekly basal insulin,in healthy participants:A randomized trial.DIABETES OBES
METAB.2023,27(5):2515-2522.
[35]X.Wang,F.Guo,C.Tang,et al.Pharmacokinetic and pharmacodynamic properties of a novel onceweekly insulin analogue GZR4 in people with type 2 diabetes.https://cattendee.abstractsonline.com/meeting/20620/session/279.
[36]Three Innovative Drugs:GZR18 Injection,GZR4 Injection,and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies.https://www.biospace.com/press-releases/gan-lee
pharmaceuticals-three-innovative-drugs gzr18-injection-gzr4-injection-and-gzr101-
injection-achieve-primary-endpoints-in-phase-2-clinical-studies?use_xbridge3=true&loader_
name=forest&need_sec_link=1&sec_link_scene=im.
